M
Mizuki Nishino
Researcher at Brigham and Women's Hospital
Publications - 284
Citations - 15732
Mizuki Nishino is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 52, co-authored 239 publications receiving 11362 citations. Previous affiliations of Mizuki Nishino include Beth Israel Deaconess Medical Center & Queen Mary University of London.
Papers
More filters
Journal ArticleDOI
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Ferdinandos Skoulidis,Michael E. Goldberg,Danielle Greenawalt,Matthew D. Hellmann,Mark M. Awad,Justin F. Gainor,Alexa B. Schrock,Ryan J. Hartmaier,Sally E. Trabucco,Siraj M. Ali,Julia A. Elvin,Gaurav Singal,Jeffrey S. Ross,David Fabrizio,Péter Szabó,Han Chang,Ariella Sasson,Sujaya Srinivasan,Stefan Kirov,Joseph D. Szustakowski,Patrik Vitazka,Robin Edwards,Jose A. Bufill,Neelesh Sharma,Sai-Hong Ignatius Ou,Nir Peled,Nir Peled,David R. Spigel,Hira Rizvi,Elizabeth Jimenez Aguilar,Brett W. Carter,Jeremy J. Erasmus,Darragh Halpenny,Andrew J. Plodkowski,Niamh Long,Mizuki Nishino,Warren Denning,Ana Galan-Cobo,Haifa Hamdi,Taghreed Hirz,Pan Tong,Jing Wang,Jaime Rodriguez-Canales,Pamela Villalobos,Edwin Roger Parra,Neda Kalhor,Lynette M. Sholl,Jennifer L. Sauter,Achim A. Jungbluth,Mari Mino-Kenudson,Roxana Azimi,Yasir Elamin,Jianjun Zhang,Giulia Costanza Leonardi,Fei Jiang,Fei Jiang,Kwok-Kin Wong,J. Jack Lee,Vassiliki A. Papadimitrakopoulou,Ignacio I. Wistuba,Vincent A. Miller,Garrett M. Frampton,Jedd D. Wolchok,Alice T. Shaw,Pasi A. Jänne,Philip J. Stephens,Charles M. Rudin,William J. Geese,Lee A. Albacker,John V. Heymach +69 more
TL;DR: Genomic profiling may enhance the predictive utility of PD-L1 expression and tumor mutation burden and facilitate establishment of personalized combination immunotherapy approaches for genomically defined LUAC subsets.
Journal ArticleDOI
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
TL;DR: The biological mechanisms underlying the unconventional response patterns associated withICB are reviewed, strategies for the objective assessments of such responses are described, and ongoing efforts to identify biomarkers are highlighted, in order to guide treatment with ICB.
Journal ArticleDOI
Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis
TL;DR: The incidence of PD-1 inhibitor-related pneumonitis was higher in NSCLC and RCC and during combination therapy and these findings contribute to awareness among clinicians to meet the clinical needs.
Journal ArticleDOI
Lung Volumes and Emphysema in Smokers with Interstitial Lung Abnormalities
George R. Washko,Gary M. Hunninghake,Isis E. Fernandez,Mizuki Nishino,Yuka Okajima,Tsuneo Yamashiro,James C. Ross,Raúl San José Estépar,David A. Lynch,John Brehm,Katherine P. Andriole,Alejandro A. Diaz,Ramin Khorasani,Katherine D'Aco,Frank C. Sciurba,Edwin K. Silverman,Hiroto Hatabu,Ivan O. Rosas +17 more
TL;DR: In smokers, interstitial lung abnormalities were associated with reduced total lung capacity and a lesser amount of emphysema and were positively associated with both greater exposure to tobacco smoke and current smoking.
Journal ArticleDOI
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Zhao Chen,Katherine A. Cheng,Zandra E. Walton,Yuchuan Wang,Hiromichi Ebi,Takeshi Shimamura,Yan Liu,Tanya Tupper,Jing Ouyang,Jie Li,Peng Gao,Michele S. Woo,Chunxiao Xu,Masahiko Yanagita,Abigail Altabef,Shumei Wang,Charles Lee,Yuji Nakada,Christopher G. Peña,Yanping Sun,Yoko Franchetti,Catherine Yao,Amy Saur,Michael D. Cameron,Mizuki Nishino,D. Neil Hayes,Matthew D. Wilkerson,Patrick J. Roberts,Carrie B. Lee,Nabeel Bardeesy,Mohit Butaney,Lucian R. Chirieac,Daniel B. Costa,David M. Jackman,Norman E. Sharpless,Diego H. Castrillon,George D. Demetri,Pasi A. Jänne,Pier Paolo Pandolfi,Lewis C. Cantley,Andrew L. Kung,Jeffrey A. Engelman,Kwok-Kin Wong +42 more
TL;DR: It is demonstrated that concomitant loss of either p53 or Lkb1, two clinically relevant tumour suppressors, markedly impaired the response of Kras-mutant cancers to docetaxel monotherapy, highlighting the rationale for synchronous co-clinical trials.